Integrated DNA Technologies Expands Manufacturing Capacity to Boost Cancer Research Solutions
Integrated DNA Technologies expands its Coralville facility, tripling production capacity to support faster, scalable solutions for cancer research and next-generation sequencing applications.
Global Pharma | 22/04/2026 | By News Bureau | 261
Syntegon Posts Record Year in 2025 and Aims for Further Growth
Syntegon reports a record 2025 with revenue up 10 percent to €1.75 billion and pharma sales surging 22 percent, alongside strong EBITDA and cash flow growth, reinforcing its position as a key lifecycle partner for pharma, biotech and food industries.
Global Pharma | 21/04/2026 | By News Bureau | 313
Interna Therapeutics and Daiichi Sankyo Partner to Advance MNM-Based Targeted Delivery Technology
Interna Therapeutics and Daiichi Sankyo collaborate to advance MNM-based targeted delivery technologies, aiming to enhance intracellular delivery, boost therapeutic activity, and improve performance across key drug development programs.
Global Pharma | 17/04/2026 | By News Bureau | 168
Mabwell Strengthens China Pipeline with NMPA Acceptance for Denosumab
Mabwell announces NMPA acceptance of its sBLA for MAIWEIJIAN (denosumab), China’s first approved 120mg denosumab biosimilar, used to treat giant cell tumor of bone in adults and adolescents.
Global Pharma | 17/04/2026 | By News Bureau | 134
Kazia Expands Oncology Platform with First-in-Class SETDB1 Inhibitor
Kazia Therapeutics expands its oncology platform with a first-in-class SETDB1 inhibitor, leveraging an AI-driven epigenetic drug discovery engine for faster and scalable candidate development.
Global Pharma | 15/04/2026 | By News Bureau | 189
Ifinatamab Deruxtecan Gets US Priority Review for Small Cell Lung Cancer
Ifinatamab deruxtecan receives US Priority Review for Small Cell Lung Cancer, supported by Phase 2 data, with potential as a first-in-class B7-H3 targeted Antibody Drug Conjugate.
Global Pharma | 13/04/2026 | By News Bureau | 237
Daiichi Sankyo Partners with Imagene AI for Biomarker Discovery
Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.
Global Pharma | 11/04/2026 | By News Bureau | 222
Inventia Healthcare Launches Generic Dapagliflozin in US After FDA Approval
Inventia Healthcare has secured FDA approval for dapagliflozin tablets and begun Day-One commercialisation, expanding access to affordable diabetes and heart failure treatment in the US.
Global Pharma | 09/04/2026 | By News Bureau | 379
Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer
The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.
Global Pharma | 08/04/2026 | By News Bureau | 151
Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration
The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.
Global Pharma | 08/04/2026 | By News Bureau | 135
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy